We are live on ! Find out more
AKRO

Akero Therapeutics
AKRO

Delisted

AKRO was delisted on the 8th of December, 2025.

Back to rankings

54 hedge funds and large institutions have $288M invested in Akero Therapeutics in 2019 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 8

41% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 17

41% more capital invested

Capital invested by funds: $205M → $288M (+$83.7M)

13% more funds holding

Funds holding: 48 → 54 (+6)

5.15% more ownership

Funds ownership: 39.46% → 44.62% (+5.2%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
54
Holders Change
+6
Holders Change %
+12.5%
% of All Funds
1.18%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
24
Increased
13
Reduced
8
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$29.5M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$9.97M
3
HA
HHLR Advisors
Cayman Islands
+$7.55M
4
Alkeon Capital Management
Alkeon Capital Management
New York
+$6.56M
5
BlackRock
BlackRock
New York
+$3.76M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$4.11M
2
FCM
Farallon Capital Management
California
-$2.87M
3
Millennium Management
Millennium Management
New York
-$2.19M
4
MIM
Monashee Investment Management
Massachusetts
-$2.11M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$1.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$594K -$746K -32,040 -55%
Citadel Advisors
27
Citadel Advisors
Florida
$528K +$540K +23,219 New
CS
28
Candriam SCA
Luxembourg
$455K – – –
Squarepoint
29
Squarepoint
New York
$429K +$439K +18,874 New
Bank of New York Mellon
30
Bank of New York Mellon
New York
$250K +$255K +10,967 New
Bank of Montreal
31
Bank of Montreal
Ontario, Canada
$238K +$242K +10,418 New
TD Asset Management
32
TD Asset Management
Ontario, Canada
$235K +$240K +10,322 New
California State Teachers Retirement System (CalSTRS)
33
California State Teachers Retirement System (CalSTRS)
California
$169K +$173K +7,447 New
UBS Group
34
UBS Group
Switzerland
$139K +$116K +4,990 +446%
New York State Common Retirement Fund
35
New York State Common Retirement Fund
New York
$121K +$123K +5,300 New
AIG
36
American International Group
New York
$69K +$70.2K +3,018 New
TAM
37
Tiverton Asset Management
Delaware
$64K – – –
Barclays
38
Barclays
United Kingdom
$61K +$61.8K +2,657 New
Victory Capital Management
39
Victory Capital Management
Texas
$60K +$23.8K +1,021 +63%
CSS
40
Cubist Systematic Strategies
Connecticut
$59K -$45.5K -1,957 -43%
Bank of America
41
Bank of America
North Carolina
$46K +$45.6K +1,961 New
Morgan Stanley
42
Morgan Stanley
New York
$38K +$36.3K +1,562 +1,562%
SO
43
STRS Ohio
Ohio
$29K +$30.3K +1,300 New
Deutsche Bank
44
Deutsche Bank
Germany
$29K +$30.6K +1,317 New
GHCM
45
Glen Harbor Capital Management
California
$17K – – –
Legal & General Group
46
Legal & General Group
United Kingdom
$17K +$17.7K +759 New
MCIM
47
Meadow Creek Investment Management
Georgia
$14K – – –
BNP Paribas Financial Markets
48
BNP Paribas Financial Markets
France
$13.7K +$14.1K +604 New
EP
49
Elkfork Partners
Oregon
$11K – – –
Wells Fargo
50
Wells Fargo
California
$9K +$8.98K +386 New
1
2
3

AKRO Hedge Fund Activity: Q3 2019 in Review

54 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q3 2019, worth a combined $288M — up 41% from $205M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new AKRO positions and 17 closed out — a net gain of 7 holders — while 13 added to existing stakes and 8 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $29.5M. The largest seller was BVF Inc, cutting an estimated $4.11M.

  • 54 institutional investors held Akero Therapeutics (AKRO) as of Q3 2019, up from 48 in Q2 2019.
  • Funds reported $288M of Akero Therapeutics stock for Q3 2019, up 41% quarter-over-quarter.
  • 24 funds opened new Akero Therapeutics positions in Q3 2019 and 17 closed out, a net change of +7 holders.
  • The largest Akero Therapeutics buyer in Q3 2019 was Janus Henderson Group, an estimated $29.5M added.
  • The largest Akero Therapeutics seller in Q3 2019 was BVF Inc, an estimated $4.11M sold.

Based on aggregated 13F filings for Q3 2019.